Sana Biotechnology SANA 深 沪
已收盘 09-18 16:00:00 美东时间
3.10
0.000
0.00%
华盛通- 最 高3.11
- 今 开3.09
- 成交量 740.90万股
- 最 低 3.02
- 昨 收 3.10
- 总市值 9.28亿
- 52周最高 6.55
- 市盈率 静 --
- 换手率 2.47%
- 52周最低 2.61
- 委 比 -22.04%
- 总股本 2.99亿
- 历史最高 44.60
- 量 比 1.78
- 振 幅 2.90%
- 历史最低 1.26
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6
B of A Securities analyst Alex Stranahan maintains Sana Biotechnology (NASDAQ:SANA) with a Buy and lowers the price target from $7 to $6.
08-15 02:19
财报速睇 | Sana Biotechnology 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.64亿美元，同比亏损缩窄32.2%
华盛资讯8月11日讯，Sana Biotechnology公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.64亿美元，同比亏损缩窄32.2%。
08-11 06:04
财报速睇 | Sana Biotechnology 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.64亿美元，同比亏损缩窄31.9%
华盛资讯8月11日讯，Sana Biotechnology公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.64亿美元，同比亏损缩窄31.9%。
08-11 05:19
Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the same period last year.
08-11 05:04
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Sana Biotechnology announced that a peer-reviewed letter published in The New England Journal of Medicine highlights 14-month follow-up data from a study of UP421, a HIP-modified pancreatic islet cell therapy for type 1 diabetes. The study demonstrates that HIP-modified cells are safe, evade immune rejection, and maintain long-term insulin production without immunosuppression. Sana plans to file an IND application and initiate a Phase 1/2 trial f...
07-13 12:00
Sana Biotechnology raises $69M through ATM share sale
Sana Biotechnology (SANA) said on Friday it sold about 21.6M shares through its at-the-market facility with TD Securities, generating net proceeds of roughly $69M. The company said the financing, toge...
05-15 21:26
Sana Biotechnology Presents Preclinical Data Showing Surrogate SG293 Achieves Cell-Specific Delivery, Dose-Dependent CAR T Cell Generation, And Deep B Cell Depletion In NHPs At ASGCT 2026 Annual Meeting
Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of preclinical data demonstrating that a surrogate SG293,
05-13 04:20
Sana Biotechnology Q1 Adj. EPS $(0.14) Beats $(0.17) Estimate
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 30 percent increase over losses of $(0.20) per share from
05-12 04:25
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
